Baseline patient demographics and disease characteristics by disease duration
| Duration of RA | Tofacitinib 5 mg two times a day | Tofacitinib 10 mg two times a day | MTX | |||
|---|---|---|---|---|---|---|
| Early (n=201) | Established (n=172) | Early (n=207) | Established (n=190) | Early (n=107) | Established (n=79) | |
| Demographics | ||||||
| Female, n (%) | 147 (73.1) | 139 (80.8) | 162 (78.3) | 165 (86.8) | 87 (81.3) | 58 (73.4) |
| Caucasian, n (%) | 135 (67.2) | 104 (60.5) | 131 (63.3) | 135 (71.1) | 77 (72.0) | 50 (63.3) |
| Mean age, years | 50.2 | 50.5 | 48.1 | 50.7 | 47.9 | 50.1 |
| Mean disease duration, years | 0.32 | 6.01 | 0.31 | 6.71 | 0.35 | 5.98 |
| Disease characteristics* | ||||||
| TJC | 26.0 | 25.2 | 25.2 | 25.0 | 24.7 | 26.4 |
| SJC | 15.9 | 16.7 | 16.0 | 15.1 | 17.4 | 16.0 |
| vdHmTSS | 8.6 | 31.6 | 5.0 | 31.4 | 7.8 | 27.8 |
| Erosion score | 4.5 | 14.4 | 2.8 | 15.5 | 4.4 | 13.9 |
| HAQ-DI | 1.47 | 1.62 | 1.49 | 1.51 | 1.49 | 1.57 |
| DAS28-4(ESR) | 6.53 | 6.72 | 6.52 | 6.57 | 6.53 | 6.70 |
| hsCRP, mg/dL | 22.7 | 22.7 | 21.0 | 19.5 | 24.9 | 27.3 |
| RF positive, % | 82.6 | 82.0 | 80.2 | 83.2 | 83.2 | 86.1 |
| ACPA positive, % | 85.1 | 84.9 | 82.6 | 79.5 | 79.4 | 96.2 |
Early RA was defined as disease duration <1 year, and established RA was defined as disease duration ≥1 year.
*Mean values, unless otherwise specified.
ACPA, anticyclic citrullinated peptide antibodies; DAS28-4(ESR), Disease Activity Score in 28 joints (erythrocyte sedimentation rate); HAQ-DI, Health Assessment Questionnaire-Disability Index; hsCRP, high sensitivity C reactive protein; MTX, methotrexate; n, number of patients; RA, rheumatoid arthritis; RF, rheumatoid factor; SJC, swollen joint count; TJC, tender joint count; vdHmTSS, van der Heijde modification of the total Sharp score.